List of bibliographic references
Number of relevant bibliographic references: 20.
Ident. | Authors (with country if any) | Title |
---|
000437 (2009) |
WAI HAUNG YU [États-Unis] ; Beatriz Dorado [États-Unis] ; Helen Yvette Figueroa [États-Unis] ; LILI WANG [États-Unis] ; Emmanuel Planel [Canada] ; Mark R. Cookson [États-Unis] ; Lorraine N. Clark [États-Unis] ; Karen E. Duff [États-Unis] | Metabolic Activity Determines Efficacy of Macroautophagic Clearance of Pathological Oligomeric α-Synuclein |
000613 (2007) |
YU YAO [Canada] ; Amandio Vieira [Canada] | Protective activities of Vacciniutn antioxidants with potential relevance to mitochondrial dysfunction and neurotoxicity |
000966 (2003) |
Pierre J. Blanchet [États-Unis, Canada] ; Spiros Konitsiotis [États-Unis, Grèce] ; Hideki Mochizuki [États-Unis, Japon] ; Ryszard Pluta [États-Unis] ; Dwaine F. Emerich [États-Unis] ; Thomas N. Chase [États-Unis] ; M. Maral Mouradian [États-Unis] | Complications of a trophic xenotransplant approach in parkinsonian monkeys |
000A50 (2001) |
Wakako Maruyama [Japon] ; Yukihiro Akao [Japon] ; Moussa B. H. Youdim [Israël] ; Bruce A. Davis [Canada] ; Makoto Naoi [Japon] | Transfection-enforced Bcl-2 overexpression and an anti-Parkinson drug, rasagiline, prevent nuclear accumulation of glyceraldehyde-3-phosphate dehydrogenase induced by an endogenous dopaminergic neurotoxin, N-methyl(R)salsolinol |
000B36 (2001) |
Daniel S. Sa [Canada] ; Shitij Kapur [Canada] ; Anthony E. Lang [Canada] | Amoxapine shows an antipsychotic effect but worsens motor function in patients with Parkinson's disease and psychosis |
000B46 (2000) |
D. J. Chong [Canada] ; O. Suchowersky [Canada] ; C. Szumlanski [États-Unis] ; R. M. Weinshilboum [États-Unis] ; R. Brant [Canada] ; N. R. C. Campbell [Canada] | The relationship between COMT genotype and the clinical effectiveness of tolcapone, a COMT inhibitor, in patients with Parkinson's Disease |
000B50 (2000) |
James N. Oak [Canada] ; John Oldenhof [Canada] ; Hubert H. M. Van Tol [Canada] | The dopamine D4 receptor : one decade of research |
000B53 (2000) |
ABDALLAH HADJ TAHAR [Canada] ; Laurent Gregoire [Canada] ; Evelyne Bangassoro [Canada] ; Paul J. Bedard [Canada] | Sustained cabergoline treatment reverses levodopa-induced dyskinesias in parkinsonian monkeys |
000B60 (2000) |
M. Goulet [Canada] ; R. Grondin [Canada] ; M. Morissette [Canada] ; S. Maltais [Canada] ; P. Falardeau [Canada] ; P. J. Bedard [Canada] ; T. Di Paolo [Canada] | Regulation by chronic treatment with cabergoline of dopamine D1 and D2 receptor levels and their expression in the striatum of Parkinsonian-Monkeys |
000B96 (2000) |
M. Cyr [Canada] ; F. Calon [Canada] ; M. Morissette [Canada] ; M. Grandbois [Canada] ; S. Callier [Canada, France] ; T. Di Paolo [Canada] | Drugs with estrogen-like potency and brain activity : Potential therapeutic application for the CNS |
000C07 (2000) |
ABDALLAH HADJ TAHAR [Canada] ; N. Belanger [Canada] ; E. Bangassoro [Canada] ; L. Gregoire [Canada] ; P. J. Bedard [Canada] | Antidyskinetic effect of JL-18, a clozapine analog, in parkinsonian monkeys |
000C24 (1999) |
Juan Fernandez-Ruiz [États-Unis] ; Doris Doudet [Canada] ; Thomas G. Aigner [États-Unis] | Spatial memory improvement by levodopa in parkinsonian MPTP-treated monkeys |
000C60 (1999) |
V. D. Doan [Canada] ; R. Grondin [Canada] ; ABDALLAH HADJ TAHAR [Canada] ; L. Gregoire [Canada] ; P. J. Bedard [Canada] | Effect of the selective D1 antagonists SCH 23390 and NNC 01-0112 on the delay, duration, and improvement of behavioral responses to dopaminergic agents in MPTP-treated monkeys |
000D60 (1997) |
C.-T. Lai [Canada] ; P. H. Yu [Canada] | R(-)-deprenyl potentiates dopamine induced cytotoxicity toward catecholaminergic neuroblastoma SH-SY5Y cells |
000E07 (1996) |
MANOHAR LAL THAKUR [Canada] ; UMA SHANKAR SRIVASTAVA [Canada] | Vitamin-E metabolism and its application |
000E72 (1995) |
P. J. Bedard [Canada] | D-1 receptor in neurology and psychiatry : an overview : The role of D-1 dopamine receptors in neurology and psychiatry |
001032 (1991) |
O. S. Kofman [Canada] | Deprenyl : protective vs. symptomatic effect |
001067 (1990) |
P. Seeman ; H. B. Niznik | Dopamine receptors and transporters in Parkinson's disease and schizophrenia |
001093 (1989) |
G. S. Robertson ; D. G. Herrera ; M. Dragunow ; H. A. Robertson | L-DOPA activates c-fos in the striatum ipsilateral to a 6-hydroxydopamine lesion of the substantia nigra |
001100 (1989) |
E. C. Wolters ; T. A. Hurwitz ; R. F. Peppard ; D. B. Calne | Clozapine: an antipsychotic agent in Parkinson's disease? |
List of associated Author.i
Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Canada/explor/ParkinsonCanadaV1/Data/PascalFrancis/Checkpoint
HfdIndexSelect -h $EXPLOR_AREA/Data/PascalFrancis/Checkpoint/FC03.fr.i -k "Activité biologique"
HfdIndexSelect -h $EXPLOR_AREA/Data/PascalFrancis/Checkpoint/FC03.fr.i \
-Sk "Activité biologique" \
| HfdSelect -Kh $EXPLOR_AREA/Data/PascalFrancis/Checkpoint/biblio.hfd
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Canada
|area= ParkinsonCanadaV1
|flux= PascalFrancis
|étape= Checkpoint
|type= indexItem
|index= FC03.fr.i
|clé= Activité biologique
}}
| This area was generated with Dilib version V0.6.29. Data generation: Thu May 4 22:20:19 2017. Site generation: Fri Dec 23 23:17:26 2022 | ![](Common/icons/LogoDilib.gif) |